Remove 2023 Remove Biotechnology Remove Contract research organization Remove Utilities
article thumbnail

Avance Clinical Earns Frost & Sullivan’s 2023 Best Practices Customer Value Leadership Award for Delivering High-quality Clinical Trials Based on Globally Accepted Data

Frost & Sullivan

San Antonio, TX — 7 th Aug, 2023 — Frost & Sullivan recently researched the Asia-Pacific biotechnology contract research organization industry and, based on its findings, recognizes Avance Clinical with the 2023 Customer Value Leadership Award. In addition, the attractive 43.5%

article thumbnail

Top 10 Strategic Imperatives Driving Innovation in AI-Enhanced Drug Discovery and Development

Frost & Sullivan

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. increase from 2022. However, the pharma/biopharma industry overall shows stagnant R&D activity. Total R&D expenditure is approximately $276.81